Publications
Discover peer-reviewed publications by therapeutic area.
The information on this page pertains to select publication resources. It is not intended to serve as a comprehensive list of all publications resources.
If you would like to discover more educational content, please use the “Search” feature.
Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
The provision of this content is not intended to recommend or suggest use of its products in any manner inconsistent with local regulatory approval. For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Transthyretin Amyloidosis (ATTR)
Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy
European Journal of Heart Failure
Primary Hyperoxaluria Type 1 (PH1)
Distinguishing characteristics of pediatric patients with primary hyperoxaluria type 1 in PEDSnet
Journal of Pediatric Urology
Acute Hepatic Porphyria (AHP)
Clinical features of acute attacks, chronic symptoms, and long-term complications among patients with acute hepatic porphyria in Japan: a real-world claims database study
Orphanet Journal of Rare Diseases
Transthyretin Amyloidosis (ATTR)
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
New England Journal of Medicine
Primary Hyperoxaluria Type 1 (PH1)
Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study
BMC Nephrology
Transthyretin Amyloidosis (ATTR)
Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation
Clinical Pharmacokinetics
Transthyretin Amyloidosis (ATTR)
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
Neurology and Therapy
Cardiovascular (CV)
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
New England Journal of Medicine
Acute Hepatic Porphyria (AHP)
Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial
Journal of Hepatology
